

# Artificial Intelligence and Machine Learning

Businesses adopting artificial intelligence and machine learning technologies and the companies developing them turn to us to navigate regulatory complexities, potential liabilities, and transactional considerations they face on the path to realizing AI's tremendous potential.

We bring together our extensive technical backgrounds and broad range of subject matter experience to help them:

- identify potential risks through data protection impact assessments;
- navigate whether AI's role is categorized as a medical device by the FDA;
- maneuver through ambiguous FDA guidelines related to AI in drug development;
- counsel on the murky landscape of copyright law in connection with generative AI;
- comply with digital communication laws regarding the use of AI systems in content moderation and advertising;
- ensure the use of AI systems is done in an ethical and responsible fashion;
- mitigate risks from contractual, e-discovery, product liability, regulatory, and tort-based claims; and
- complement their businesses and expand into new markets through investments in and acquisitions of sophisticated AI platforms.

From major corporations to emerging growth companies and their investors, we provide this guidance across the full range of AI/ML technologies including:

- fraud detection and digital identity;

## Capability Lawyers



Carolyn Zander Alford  
*Atlanta*



John M. Anderson  
*Atlanta*



Lisa M. Dwyer  
*Washington, D.C.*



Amanda J. Klingler  
*Washington, D.C.*



Phyllis B. Sumner  
*Atlanta*



Rose J. Jones  
*Atlanta*

- digital health and personalized medicine;
- chatbots;
- e-commerce and marketplace platforms;
- facial/biometric data recognition;
- intelligent robotics;
- autonomous vehicles;
- data set licensing; and more.

## Cases & Deals

*August 10, 2021*

Equifax to Acquire Appriss Insights for \$1.825 billion

*July 15, 2021*

HeartFlow To Go Public in SPAC Merger

*April 6, 2021*

Sidetrade acquires Amalto

[VIEW ALL](#)

---

## Insights

**ARTICLE**

*April 3, 2024*

Federal Enforcers Signal Heightened Scrutiny of Algorithm Use to Inform Pricing Decisions

**CLIENT ALERT**

*March 28, 2024*

Executive Order Restricts Foreign Access to U.S. Data, Citing National Security Risks

**CLIENT ALERT**

*March 25, 2024*

FDA Publishes White Paper on Artificial Intelligence & Medical Products

[VIEW ALL](#)

---

## Events

**SPEAKING ENGAGEMENT**

*May 28, 2024*

Kassi Burns to Speak on the Beverly Hills Bar Association's Webinar

**SPEAKING ENGAGEMENT**

*May 14, 2024*

Rose Jones to Speak on American Bar Association Webinar

**SPEAKING ENGAGEMENT**

*April 24, 2024*

Rose Jones to Speak at the AI Bootcamp

[VIEW ALL](#)

---

## News

### IN THE NEWS

*April 8, 2024*

Lisa Dwyer comments on the FDA's drug center gearing up to issue guidance on use of artificial intelligence to enhance its regulatory decision-making

### IN THE NEWS

*April 5, 2024*

Dan Kahan comments on a new report from the U.S. Treasury Department examining the growing vulnerability of the financial services industry to cyber-enabled fraud perpetrated by bad actors wielding AI tools

### IN THE NEWS

*March 13, 2024*

Lazar Raynal, Michael Lombardo, Julia Barrett, Bob Cooper and Chris Yook counsel Tractable in a trade secrets dispute with CCC Intelligent Solutions before an Illinois federal court

[VIEW ALL](#)

---